Cargando…

Comparative Safety and Changes in Immunologic and Virologic Parameters of Dolutegravir versus Efavirenz-Based Antiretroviral Therapies Among HIV Patients: A Retrospective Cohort Study

BACKGROUND: In combination with other two antiretroviral drugs, an efavirenz (EFV) or dolutegravir (DTG)-based regimen is the treatment of choice for human immunodeficiency virus (HIV) infection. This study aimed to determine the safety and changes in immunologic and virologic parameters of DTG comp...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ayal, Melese Alemnew, Berha, Alemseged Beyene
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2023
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10150766/ https://www.ncbi.nlm.nih.gov/pubmed/37139483 http://dx.doi.org/10.2147/HIV.S396420

Ejemplares similares

Predictors of treatment failure, time to switch and reasons for switching to second line antiretroviral therapy in HIV infected children receiving first line anti-retroviral therapy at a Tertiary Care Hospital in Ethiopia
por: Haile, Gelila Solomon, et al.
Publicado: (2019)

Dolutegravir plus lamivudine versus efavirenz plus tenofovir disoproxil fumarate and lamivudine in antiretroviral-naive adults with HIV-1 infection
por: Deng, Lisi, et al.
Publicado: (2022)

Dolutegravir: Virologic response and tolerability of initial antiretroviral regimens for adults living with HIV
por: Correa, Analú, et al.
Publicado: (2020)

Treatment Outcomes of Dolutegravir- Versus Efavirenz-Based Highly Active Antiretroviral Therapy Regimens Among Treatment-Naive People Living With HIV
por: Mahale, Prarthana R, et al.
Publicado: (2023)

Comparative safety of dolutegravir-based or efavirenz-based antiretroviral treatment started during pregnancy in Botswana: an observational study
por: Zash, Rebecca, et al.
Publicado: (2018)

Suppression of HIV in the first 12 months of antiretroviral therapy: a comparative analysis of dolutegravir- and efavirenz-based regimens
por: da Silva, Gabriella Jomara, et al.
Publicado: (2023)

Safety and Efficacy of COVID-19 Vaccine in Africa: Systematic Review
por: Mengstu, Selamawit, et al.
Publicado: (2023)

Concentration-Response Relationships of Dolutegravir and Efavirenz with Weight Change After Starting Antiretroviral Therapy
por: Griesel, Rulan, et al.
Publicado: (2022)

Antiretroviral drugs efavirenz, dolutegravir and bictegravir dysregulate blood-brain barrier integrity and function
por: Huang, Chang, et al.
Publicado: (2023)

Immunological, Cognitive, and Psychiatric Outcomes After Initiating Efavirenz- and Dolutegravir-based Antiretroviral Therapy During Acute Human Immunodeficiency Virus Infection
por: Chan, Phillip, et al.
Publicado: (2022)

Efavirenz versus boosted atazanavir-containing regimens and immunologic, virologic, and clinical outcomes: A prospective study of HIV-positive individuals
por: Cain, Lauren E., et al.
Publicado: (2016)

Patient experiences of switching from Efavirenz- to Dolutegravir-based antiretroviral therapy: a qualitative study in Uganda
por: Twimukye, Adelline, et al.
Publicado: (2021)

Real-world efficacy and safety of dolutegravir plus lamivudine versus tenofovir plus lamivudine and efavirenz in ART-naïve HIV-1-infected adults
por: Li, Jin, et al.
Publicado: (2022)

Effects of enzyme inducers efavirenz and tipranavir/ritonavir on the pharmacokinetics of the HIV integrase inhibitor dolutegravir
por: Song, Ivy, et al.
Publicado: (2014)

Updated assessment of risks and benefits of dolutegravir versus efavirenz in new antiretroviral treatment initiators in sub-Saharan Africa: modelling to inform treatment guidelines
por: Phillips, Andrew N, et al.
Publicado: (2020)

A randomized comparison of health-related quality of life outcomes of dolutegravir versus efavirenz-based antiretroviral treatment initiated in the third trimester of pregnancy
por: Ochanda, Perez Nicholas, et al.
Publicado: (2022)

Management Practice and Clinical Outcomes of Dementia in Sub-Saharan Africa: A Systematic Review
por: Beyene, Dessale Abate, et al.
Publicado: (2023)

A retrospective clinical study of dolutegravir- versus efavirenz-based regimen in treatment-naïve patients with advanced HIV infection in Nanjing, China
por: Zhong, Mingli, et al.
Publicado: (2023)

Cost-effectiveness of dolutegravir vs. efavirenz-based combined antiretroviral therapies in HIV-infected treatment-naive patients in a Nigerian treatment centre
por: Isah, Abdulmuminu, et al.
Publicado: (2023)

Comparative efficacy, tolerability and safety of dolutegravir and efavirenz 400mg among antiretroviral therapies for first-line HIV treatment: A systematic literature review and network meta-analysis
por: Kanters, Steve, et al.
Publicado: (2020)

Clinical, Immunological and Virological Responses of Zidovudine-Lamivudine-Nevirapine versus Zidovudine-Lamivudine-Efavirenz Antiretroviral Treatment (ART) Among HIV-1 Infected Children: Asella Teaching and Referral Hospital, South-East Ethiopia
por: Sorsa, Abebe
Publicado: (2018)

Dolutegravir Plus Two Nucleoside Reverse Transcriptase Inhibitors versus Efavirenz Plus Two Nucleoside Reverse Transcriptase Inhibitors As Initial Antiretroviral Therapy for People with HIV: A Systematic Review
por: Rutherford, George W., et al.
Publicado: (2016)

Current Practice and Barriers to an Early Antimicrobial Conversion from Intravenous to Oral among Hospitalized Patients at Jimma University Specialized Hospital: Prospective Observational Study
por: Beyene Berha, Alemseged, et al.
Publicado: (2019)

Prevalence and predictors of drug-related hospitalisation among patients visiting emergency departments of Addis Ababa city hospitals in Ethiopia: a multicentre prospective observational study
por: Demessie, Mulate Belete, et al.
Publicado: (2022)

Immunological failure despite virological suppression in HIV seropositive individuals on antiretroviral therapy
por: Prabhakar, B., et al.
Publicado: (2011)

Lamivudine/dolutegravir dual therapy in HIV-infected, virologically suppressed patients
por: Maggiolo, Franco, et al.
Publicado: (2017)

Virologic response to efavirenz-based first-line antiretroviral therapy in children with previous exposure to antiretrovirals to prevent mother-to-child transmission
por: Nyakato, Patience, et al.
Publicado: (2020)

Cost-Utility Analysis of Dolutegravir- Versus Efavirenz-Based Regimens as a First-Line Treatment in Adult HIV/AIDS Patients in Ethiopia
por: Belay, Yared Belete, et al.
Publicado: (2021)

Drug resistance in HIV patients with virological failure or slow virological response to antiretroviral therapy in Ethiopia
por: Abdissa, Alemseged, et al.
Publicado: (2014)

Risk of Cardiovascular Events Among Patients Initiating Efavirenz-Containing Versus Efavirenz-Free Antiretroviral Regimens
por: Rosenblatt, Lisa, et al.
Publicado: (2016)

The relation between efavirenz versus nevirapine and virologic failure in Johannesburg, South Africa
por: Shearer, Kate, et al.
Publicado: (2014)

Nevirapine or efavirenz for tuberculosis and HIV coinfected patients: exposure and virological failure relationship
por: Bhatt, Nilesh B., et al.
Publicado: (2015)

Minor HIV-1 Variants with the K103N Resistance Mutation during Intermittent Efavirenz-Containing Antiretroviral Therapy and Virological Failure
por: Delobel, Pierre, et al.
Publicado: (2011)

Clinical Outcomes After Viremia Among People Receiving Dolutegravir vs Efavirenz-Based First-line Antiretroviral Therapy in South Africa
por: Asare, Kwabena, et al.
Publicado: (2023)

Greater change in bone turnover markers for efavirenz/emtricitabine/tenofovir disoproxil fumarate versus dolutegravir + abacavir/lamivudine in antiretroviral therapy-naive adults over 144 weeks
por: Tebas, Pablo, et al.
Publicado: (2015)

Concordance between modification of diet in renal disease, chronic kidney disease epidemiology collaboration and Cockcroft-Gault equations in patients with chronic kidney disease at St. Paul’s hospital millennium medical college, Addis Ababa, Ethiopia
por: Dinsa, Hunduma, et al.
Publicado: (2017)

Quality of life and associated factors among chronic kidney disease patients at Zewditu Memorial and Tikur Anbessa Specialised Hospitals, Ethiopia: a cross-sectional study design
por: Berhe, Teshome, et al.
Publicado: (2023)

Use of dolutegravir in two INI-experienced patients with multiclass resistance resulted in excellent virological and immunological responses
por: Marije Hofstra, Laura, et al.
Publicado: (2014)

Diagnostic accuracy of a point‐of‐care urine tenofovir assay, and associations with HIV viraemia and drug resistance among people receiving dolutegravir and efavirenz‐based antiretroviral therapy
por: Dorward, Jienchi, et al.
Publicado: (2023)

Immunologic and Virologic Outcomes of Obese and Nonobese Incarcerated Adults on Antiretroviral Therapy for HIV Infection
por: Bunnell, Kristen L., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_6i649mm7c2rh4lu5hb9cutahrb